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Although protein phosphorylation and dephosphorylation are known to regulate the activities of different enzymes, sufficient information
on the role of dephosphorylation in cardiac function is not available. Since protein phosphatases mediate dephosphorylation, it is possible that
cardiac dysfunction induced by diabetes may be due to alterations in the activities of these enzymes. We therefore determined cardiac protein
phosphatase activity as well as protein contents of phosphatase 1 and phosphatase 2A in diabetic animals. For this purpose, rats were made
diabetic by administering a single intravenous injection of streptozotocin (65 mg/kg body weight) and hearts were examined after 1, 2, 3, 4
and 8 weeks. Some of the 4-week diabetic animals received subcutaneous injections of insulin (3 U/day) for a further period of 4 weeks.
Cardiac dysfunction was evident after 2 weeks of inducing diabetes and deteriorated further with time. A significant increase in protein
phosphatase activity appeared after 1 week and persisted until 8 weeks. Increased protein phosphatase activity in the diabetic heart was
associated with a corresponding increase in the protein contents of both phosphatase 1 and phosphatase 2A. Insulin treatment partly
prevented the changes observed in diabetic animals. The results suggest that increased protein phosphatase activities and subsequent
enhanced protein dephosphorylation may play a role in diabetes-induced cardiac dysfunction.D 2003 Elsevier B.V. All rights reserved.Keywords: Diabetes; Protein dephosphorylation; Protein phosphatase; Diabetic heart; Cardiac dysfunction1. Introduction
Diabetes has been reported to induce cardiac dysfunction
[1–4], alterations in the activities of cardiac Ca2 +-cycling
proteins such as the sarcolemmal Na+–Ca2 +-exchanger and
L-type Ca2 +-channel [3,5,6] as well as the sarcoplasmic
reticulum (SR) Ca2 +-ATPase (SERCA2a), phospholamban
and ryanodine receptor (RyR) [1,2,4,7]. Furthermore,
changes in contractile and regulatory proteins such as
myofibrillar ATPase, troponin I and myosin light-chain have
been shown to occur in the diabetic heart [8–10]. It is
pointed out that the function of all these specialized proteins
present on sarcolemma, SR and myofibrils are modulated by
regulatory mechanisms such as protein phosphorylation and
dephosphorylation where protein kinases catalyze phosphor-0925-4439/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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phorylation reactions [11].
There is evidence to suggest abnormalities in cardiac
protein phosphorylation due to changes in the activities of
SR-associated cyclic AMP dependent protein kinase (PKA)
and calcium calmodulin-dependent protein kinase (CaMK)
as well as cytosolic and particulate protein kinase C in the
diabetic heart [12,13]. However, very little information
regarding alterations in protein phosphatases, which deter-
mine the status of cardiac protein dephosphorylation is
available in the diabetic heart. This study was therefore
undertaken to examine changes in the protein phosphatase
activity during the development of cardiac dysfunction in a
streptozotocin-induced model of diabetes in rats [1–10].
Since protein phosphatase 1 (PP1) and protein phosphatase
2A (PP2A) constitute more than 90% of the total phospha-
tases in the heart [14,15], this study also measured PP1 and
PP2A levels in the diabetic heart. The effect of insulin in
reversing the diabetes-induced changes in contractile func-
tion, protein phosphatase activity, as well as PP1 and PP2A
levels was also examined.
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2.1. Experimental model
The experimental model employed in this study is similar
to that used previously for establishing the presence of
diabetic cardiomyopathy as indicated by alterations in
cardiac function, metabolism, subcellular organelles and
ultrastructure [1–10]. Male Sprague–Dawley rats weighing
200–250 g were randomly separated into control and
experimental groups. The experimental animals received
an intravenous injection of 0.1 M citrate-buffered strepto-
zotocin (pH 4.5) at a dosage of 65 mg/kg body weight.
Control animals received a similar injection of the vehicle
alone. These animals were maintained on normal rat chow
and water ad libitum and then killed by decapitation after 1,
2, 3, and 4 weeks. Experimental animals displaying glycos-
uria (>2%) and plasma glucose elevation (>300 mg/100 ml)
were considered as the diabetic group. In another set of
experiments, a random group of diabetic animals 4 weeks
after streptozotocin injection, were administered subcutane-
ous injections of human insulin ultralente (Eli Lilly Canada,
Toronto, ON) for a further period of 4 weeks; the insulin
dose was 3 U/day. Plasma glucose and insulin levels were
determined by using the Sigma diagnostic kit (Sigma-
Aldrich Canada, Oakville, ON) and Linco rat insulin RIA
kit (Linco Research Inc., St. Charles, MO), respectively. The
in vivo cardiac function was assessed according to the
method described earlier [2,13]. Briefly, the right carotid
artery was isolated in anaesthetized animals and an ultra-
miniature catheter connected to a pressure transducer was
inserted into the left ventricle. The rate of pressure devel-
opment ( + dP/dt) and rate of pressure fall ( dP/dt) was
recorded by using a computer program, Biopac data acqui-
sition system (Biopac System Inc., Goleta, CA).
2.2. Preparation of tissue extracts
Cardiac and skeletal muscle tissue extracts for protein
phosphatase activity determination was isolated by the
method described by Foulkes and Jefferson [16]. One
hundred milligrams of cardiac left ventricle or skeletal
muscle tissue was homogenized in a buffer containing
250 mM sucrose, 4 mM EDTA, 30 mM h-mercaptoethanol
and 20 mM Tris–HCl, pH 8.3 in a homogenizer (Brink-
mann PT3000, Mississauga, Canada) at half-maximal set-
ting. The homogenates were then centrifuged at 12,000 g
for 15 min. The supernatants were subjected to sephadex
G-50 gel filtration. It has been reported that the gel
filtration step removes low molecular weight protein phos-
phatase inhibitors [17]. For this purpose, 500 Al of super-
natant was loaded on a sephadex column and eluted with a
buffer (50 mM Tris–HCl pH 7.7, 0.1 mM EDTA, 0.1%
Brij 35 and 30 mM h-mercaptoethanol). The eluate
obtained is defined as the tissue extract. All the above
steps were carried out at 4 jC.2.3. Measurement of phosphatase activities
Protein phosphatase activities were determined by using
serine/threonine protein phosphatase assay kits from Up-
state Biotechnology (Lake Placid, NY). The assay is based
on the dephosphorylation of a synthetic phosphopeptide,
KRpTIRR. The reaction was initiated by adding tissue
extracts to the synthetic peptide substrate for 5 min and
terminated by the addition of Malachite Green solution.
The absorbance was read after 15 min at 660 nM to
determine the inorganic phosphate released. The protein
phosphatase activity measured here was completely in-
hibited by okadaic acid [18]. Since no agent is currently
available to specifically inhibit PP1 or PP2A, it is difficult to
accurately measure PP1 or PP2A activities.
2.4. Analysis of PP1 and PP2A protein contents
The relative content of PP1 and PP2A proteins in cardiac
homogenates were determined by Western immunoblot anal-
ysis. Samples (20 Ag) were separated on 12% gels by SDS-
PAGE and electrophoretically transferred to Immobilon-P
transfer membranes (Millipore, Bedford, MA). Membranes
were probed with polyclonal antibodies recognizing PP1
(1:3000) and PP2A (1:2000) catalytic subunits (Santa Cruz
Biotechnology, Santa Cruz, CA). Appropriate secondary an-
tibodies were used and antigen–antibody complexes of all
probed membranes were detected by the enhanced chemilu-
minesence detection system. The intensity of each band was
scanned by an imaging densitometer with the aid of Mole-
cular Analyst Software Version 1.3 (BioRad, Hercules, CA).
2.5. Data analysis
Values are meanF S.E. and were statistically evaluated
by one-way ANOVA. P < 0.05 was considered the threshold
for statistical significance between groups.
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3.1. General characteristics and cardiac function
The data in Table 1 indicates that 8-week diabetic
animals had significantly lower body weight and ventricular
weight but exhibited a higher ventricular/body weight ratio
in comparison to control animals. The induction of diabetes
was confirmed by the presence of markedly elevated levels
of plasma glucose and severely depressed levels of plasma
insulin levels (in comparison to controls). Insulin treatment
of the 4-week diabetic animals for a period of 4 weeks
partially normalized the ventricular/body weight ratio and
plasma glucose levels as well as completely normalized
plasma insulin level. Cardiac dysfunction in diabetic ani-
mals was evident from significant depressions in the left
ventricular + dP/dt and  dP/dt in comparison to controls
Table 3
Cardiac function and protein phosphatase activities of control, 1-, 2-, 3- and
4-week diabetic rat hearts
Cardiac function (mm Hg/s) Phosphatase activities
+ dP/dt  dP/dt (Amol Pi/min/mg protein)
Control 6052F 217 5840F 243 146F 5.5
1 week 5860F 248 5614F 208 256F 15.1*
2 weeks 5476F 225 4618F 174* 203F 16.9*
3 weeks 4836F 180* 4272F 158* 201F 9.2*
4 weeks 4208F 164* 3854F 142* 199F 6.1*
Values are meanF S.E. of four experiments in each group. *Significantly
different from control (P < 0.05).
Table 1
General characteristics and cardiac function in control, diabetic and 8-week
insulin-treated diabetic animals
Control Diabetic Diabetic +
insulin
Body weight (g) 542F 22 312F 21* 354F 15
Ventricular weight (g) 998F 85 833F 40* 882F 42
Ventricular/body
weight ratio (mg/g)
1.84F 0.05 2.66F 0.01* 2.49F 0.06#
Plasma glucose (mg/dl) 165F 8.2 254F 10.2* 203F 7.0#
Plasma insulin (AU/ml) 30.1F 2.5 11.9F 0.5* 36.2F 0.8#
+ dP/dt (mm Hg/s) 5701F 244 3722F 183* 4639F 266#
 dP/dt (mm Hg/s) 5501F 320 3356F 118* 4482F 253#
Values are meanF S.E. of six animals in each group. *Significantly
different from control (P < 0.05); #significantly different from diabetic
(P < 0.05).
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insulin treatment.
3.2. Cardiac muscle protein phosphatase activities
Table 2 indicates that 8-week diabetic animals had
significantly higher cardiac muscle protein phosphatase
activities in comparison to controls. However, the protein
concentrations of cardiac muscle extracts from control and
diabetic animals were not significantly different from each
other. Insulin treatment partially normalized protein phos-
phatase activities in 8-week diabetic animals. The data in
Table 2 also indicate that 8-week diabetic animals had
significantly higher skeletal muscle protein phosphatase
activities in comparison to controls. Insulin treatment com-
pletely normalized protein phosphatase activities in 8-week
diabetic animals.
3.3. Relationship between changes in cardiac function and
cardiac phosphatase activities
In order to examine the relationship between changes in
cardiac function and cardiac protein phosphatase activities, aTable 2
Protein phosphatase activities in ventricular and skeletal muscle tissue






Control 56.7F 1.63 146F 5.5
Diabetic 57.0F 0.64 193F 5.0*
Insulin-treated
diabetic
56.2F 5.78 169F 7.6#
(B) Skeletal muscle
Control 49.2F 1.63 50F 1.9
Diabetic 48.4F 0.64 69F 2.9*
Insulin-treated
diabetic
49.2F 3.78 43F 1.5#
Values are meanF S.E. of six hearts in each group. *Significantly different
from control (P < 0.05); #significantly different from diabetic (P < 0.05).time course study was undertaken to measure these changes
in 1-, 2-, 3- and 4-week diabetic animals. The data in Table
3 indicate significantly higher protein phosphatase activities
in 1-, 2-, 3- and 4-week diabetic animals; the increase was
maximal in 1-week diabetic animals. The results in Table 3
show that there was a progressive deterioration in cardiac
function after the induction of diabetes. A significant
decrease in  dP/dt was evident after 2 weeks of inducing
diabetes, whereas + dP/dt was depressed after 3 weeks.Fig. 1. Relative protein contents of PP1 (panel A) and PP2A (panel B) in
control, 1-week (W), 2-week, 4-week, 8-week and insulin (I)-treated 8-
week diabetic rat hearts. Each value is a meanF S.E. of four experiments in
each group. *P< 0.05 vs. control; #P< 0.05 vs. 8-week diabetic animals.
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Because cardiac protein phosphatase activities were
increased in diabetic animals, the relative protein levels of
PP1 and PP2A in cardiac muscle were examined in control
animals, 1-, 2-, 4- and 8-week diabetic animals as well as
insulin-treated diabetic animals. The typical protein bands
are shown in Fig. 1. PP1 and PP2A protein bands were
identified at 37 and 36 kDa, respectively. The densitometric
analysis of bands of PP1 and PP2A revealed increases in the
respective protein levels in 1-, 2-, 4- and 8-week diabetic
animals in comparison to controls. Insulin treatment of 4-
week diabetic animals significantly attenuated the elevation
in PP1 and PP2A protein contents.
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The main finding of our study is that cardiac protein
phosphatase activity was significantly elevated in strepto-
zotocin-induced diabetic animals. An increase in protein
phosphatase activity was also observed in the diabetic
skeletal muscle. Our results are in contrast to two previous
studies that reported no changes in cardiac protein phos-
phatase activities in diabetic animals [16,19]. The variance
of results on cardiac phosphatase activities in diabetic
animals between our study and an earlier study by Foulkes
and Jefferson [16] could be due to the method of induction
of diabetes—streptozotocin-induced diabetes (in our study)
and alloxan-induced diabetes (in their study) [16]. This
appears to be a distinct possibility because we followed the
same tissue extraction method (gel filtration to remove the
endogenous inhibitors) as described in the study by
Foulkes and Jefferson in which no change in cardiac
phosphatase activity was observed in 1-week diabetic
animals. However, increased cardiac phosphatase activity
observed in our current study is consistent with our earlier
study [2] showing elevated cardiac cytosolic and SR-
associated phosphatase activities in 6-week diabetic ani-
mals. It must be pointed out that gel filtration was not used
in the latter study [2] and therefore the removal of low
molecular weight inhibitors may not influence changes in
phosphatase activities in the diabetic heart (in comparison
to controls). With regards to disparity in results between
our study and that of Jaspers and Miller [19], it must be
pointed out that besides differences in the modes of
induction in diabetes (alloxan vs. streptozotocin), Jaspers
and Miller examined the activity of highly purified phos-
phatase 2A and not cardiac phosphatase activities in
control and diabetic heart and therefore it is not possible
to make direct comparisons. However, the lack of change
in purified phosphatase 2A activity reported by Jaspers and
Miller [19] after 1 week of diabetes is consistent with no
change observed in protein content of cardiac phosphatase
2A in the diabetic heart after 1 week of diabetes in our
study.The elevation in cardiac protein phosphatase activities
was seen as early as 1 week after the induction of diabetes,
whereas abnormalities in cardiac function were evident after
2 weeks. The reduction in rate of cardiac relaxation ( dP/
dt) observed after 2 weeks in our study is in contrast to a
study by Tahiliani et al. [20], which used the same model
(streptozotocin-induced diabetes) and reported that cardiac
performance was impaired only after 6 weeks. The differ-
ence in results between both studies can be attributed to the
technique of measuring heart function. In our study, the in
vivo heart function was measured using the catheterization
technique but Tahiliani et al. [20] assessed cardiac function
ex vivo in isolated perfused hearts. Our results, however, are
supported by studies that used the same model and assessed
in vivo cardiac function by echocardiography or catheteri-
zation technique. A study by Mihm et al. [21], which
characterized a detailed time course of changes in heart
function using M-mode echocardiography reported diastolic
dysfunction in diabetic rats as early as 3 days after strepto-
zotocin administration. In another study Takeda et al. [22]
showed a slight reduction (not statistically significant) in
heart function (measured by the catheterization technique)
after only 18 days of induction of diabetes (by streptozoto-
cin administration) and significant decrease (in heart func-
tion) after 3 weeks. Thus, increased protein phosphatase
activity preceding a depression in cardiac function suggests
the possibility of enhanced protein dephosphorylation con-
tributing to cardiac dysfunction in diabetic animals. Since
the protein contents of cardiac PP1 and PP2A in diabetic
animals were elevated, the observed increase in protein
phosphatase activity might be due to increased expression
of PP1 and PP2A. Because treatment of diabetic animals
with insulin was found to prevent the increased protein
phosphatase activity as well as PP1 and PP2A contents, it is
evident that the observed changes in protein phosphatases
are due to diabetes per se.
Major Ca2 + handling and Ca2 + regulatory proteins are
known to be substrates for protein phosphatases. PP2A has
been implicated in dephosphorylation of the PKA phos-
phorylation site on the L-type Ca2 + channel that may result
in decreased channel activity [23]. Thus, an up-regulation of
PP2A may lead to marked reduction in the L-type Ca2 +
channel activity resulting in less Ca2 +, which is required for
Ca2 +-induced Ca2 + release from the SR in the diabetic
heart. On the other hand, PP1 has been reported to dephos-
phorylate the PKA phosphorylation site on the RyR that
may decrease SR Ca2 + release channel activity [24]. There-
fore, enhanced PP1 activity may cause a significant de-
crease in the SR Ca2 + release channel activity resulting in
less Ca2 + available for myofibrillar activation in the diabetic
heart. Both PP1 and PP2A have also been shown to
dephosphorylate PLB at the PKA and CaMK phosphoryla-
tion sites that may result in reduced SR Ca2 + uptake
[15,25,26]. An increase in the levels of both protein
phosphatases could thereby markedly depress SR Ca2 +
uptake and impair cardiac relaxation in the diabetic heart.
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reported to increase the phosphorylation state of TnI and
thus, enhanced protein phosphatase activities could result in
increased dephosphorylation of TnI and impairment of
cardiac relaxation in the diabetic heart. The view is further
substantiated by the observation that cardiac dysfunction
and elevated levels of PP1 and PP2A in the diabetic heart
were attenuated by insulin treatment. Thus, on the basis of
these results, we conclude that an increase in PP1 and PP2A
protein contents may contribute to cardiac dysfunction in
diabetic animals. It must however be noted that phosphatase
2A might not be involved in the functional changes that
begin early (after 2 weeks) but might contribute to changes
taking place subsequently.Acknowledgements
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